+86 400-682-2521 | order.cn@acrobiosystems.com 注册
登录 | 注册    关注公众号 |  
微信公众号
ACRO百普赛斯_logo Recombinant Proteins iso9001 ISO13485 CNAS
热门搜索：TL1A Hot|GMP细胞因子Hot|FcRn Binding Kit (TR-FRET)New|ADC定点偶联试剂盒
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
搜索
 > 【SLC34A2】

SLC34A2产品咨询

* 此表格只用于收集产品需求咨询，所有信息将严格保密。
*
*
*
*
*
*
抗体药
 
细胞治疗
 
基因治疗
 
诊断
 
疫苗
 
化药
 
蛋白及多肽药物
 
神经科学
 
XDC
 
其他
 
ACRO质量管理体系
 
评论(0)
 

SLC34A2 分子别名

SLC34A2,NaPi2b,NaPi3b

SLC34A2 分子背景

SLC34A2 (Sodium-dependent phosphate transport protein 2B) is also known Solute carrier family 34 member 2, NaPi3b, NaPi-2b. Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium. May be involved in actively transporting phosphate into cells via Na+ cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.

SLC34A2 前沿进展

SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity
Bian, Zhang, Song et al
Patterns (N Y) (2025) 6 (2), 101174
Abstract: Gene fusions are common cancer drivers and therapeutic targets, but clinical-grade open-source bioinformatic tools are lacking. Here, we introduce a fusion detection method named SplitFusion, which is fast by leveraging Burrows-Wheeler Aligner-maximal exact match (BWA-MEM) split alignments, can detect cryptic splice-site fusions (e.g., EML4::ALK v3b and ARv7), call fusions involving highly repetitive gene partners (e.g., CIC::DUX4), and infer frame-ness and exon-boundary alignments for functional prediction and minimizing false positives. Using 1,848 datasets of various sizes, SplitFusion demonstrated superior sensitivity and specificity compared to three other tools. In 1,076 formalin-fixed paraffin-embedded lung cancer samples, SplitFusion identified novel fusions and revealed that EML4::ALK variant 3 was associated with multiple fusion variants coexisting in the same tumor. Additionally, SplitFusion can call targeted splicing variants. Using data from 515 The Cancer Genome Atlas (TCGA) samples, SplitFusion showed the highest sensitivity and uncovered two cases of SLC34A2::ROS1 that were missed in previous studies. These capabilities make SplitFusion highly suitable for clinical applications and the study of fusion-defined tumor heterogeneity.© 2025 The Author(s).
A comprehensive analysis to reveal the underlying molecular mechanisms of natural killer cell in thyroid carcinoma based on single-cell RNA sequencing data
Li, Wang, Liu et al
Discov Oncol (2025) 16 (1), 44
Abstract: Thyroid carcinoma (THCA) is the most common cancer of the endocrine system. Natural killer (NK) cell play an important role in tumor immune surveillance. The aim of this study was to explore the possible molecular mechanisms involved in NK cell in THCA to help the management and treatment of the disease.All data were downloaded from public databases. Candidate hub genes associated with NK cell in THCA were identified by limma, WGCNA and singleR packages. Functional enrichment analysis was performed on the candidate hub genes. Hub genes associated with NK cell were identified by Pearson correlation analysis. The mRNA-miRNA-lncRNA and transcription factors (TF) networks were constructed and the drug was predicted.The infiltration level of NK cell in THCA tissues was higher than that in paracancerous tissues. KEGG functional enrichment analysis only obtained two signaling pathways, thyroid hormone synthesis and mineral absorption. CTSC, FN1, SLC34A2 and TMSB4X identified by Pearson correlation analysis were considered as the hub genes. Receiver operating characteristic analysis suggested that hub genes may be potential diagnostic biomarkers. In mRNA-miRNA-lncRNA network, FN1 had the highest correlation with IQCH-AS1, and IQCH-AS1 was also correlated with hsa-miR-543. In addition, FN1 and RUNX1 were also found to have the highest correlation in TF network. Finally, NK cell-related drugs belinostat and vorinostat were identified based on ASGARD.The identification of important signaling pathways, molecules and drugs provides potential research directions for further research in THCA and contributes to the development of diagnostic and therapeutic approaches for this disease.© 2025. The Author(s).
Lung Function Decline in Pulmonary Alveolar Microlithiasis
Mari, Coppola, Macagno
Cureus (2024) 16 (11), e74430
Abstract: Pulmonary alveolar microlithiasis (PAM) is a rare lung disorder characterized by calcium phosphate microliths in the alveolar spaces. Autosomal recessive mutations on the SLC34A2 gene lead to altered type IIb sodium phosphate cotransporter in alveolar type-II cells of the lung, thus resulting in aggregations of microliths in the alveoli. To date, more than 1000 cases have been reviewed by expert pulmonary clinicians. PAM is observed worldwide, with numerous cases reported in Asia and Europe. It generally progresses slowly, with symptoms commonly emerging during an individual's third or fourth decade of life. Dissociation between the clinical picture and the radiological pattern is usual. Computed tomography (CT) may show extensive radiological disease even in patients with minimal clinical symptoms. The decline in lung function is typically progressive; however, detailed information regarding specific spirometry changes remains insufficient and largely unknown. PAM management is basically supportive using vaccines, antibiotics in recurrent infections, or long-term oxygen when respiratory failure is determined. A bilateral lung transplant may be a resolutive treatment for end-stage disease. We report a lung function decline of a familial case of PAM in a 71-year-old female patient at our Interstitial Lung Disease Clinic.Copyright © 2024, Mari et al.
Showing 1-3 of 318 papers.
Powered by BizGenius

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

新闻订阅

订阅

在线留言

发送
隐私政策 | 法律法规 | 网站地图 | 加入我们
©2017 ACROBiosystems中国 京公网安备 11030102010599号 京ICP备16032159号-1

消息提示

请输入您的联系方式,再点击提交！

确定